Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomized, placebo‐controlled, phase 3 clinical trial
Keyword(s):
Phase 3
◽